The Immune Response Corp., of Carlsbad, Calif., said results of itsPhase II dose-ranging study for its HIV immunotherapeutic arebeing published in the October 1994 issue of the British journalAIDS.The study, conducted on 48 HIV-infected people in an early stageof the disease, demonstrated the ability of the immunotherapeutic tostimulate cell-mediated and antibody immune system responsesagainst HIV. The double-blind, adjuvant-controlled study alsoconfirmed the safety of the unnamed therapy.Since the Phase II trial, Immune Response, along with joint-venturepartner Rhone-Poulenc Rorer of Collegeville, Pa., have completed aPhase II/III study, and are gearing up for a large-scale Phase IIIstudy. Cindy Rollins, an investor relations associate for thecompany, said that trial is likely to get under way in 1995.Rollins said Immune Response has provided the FDA withinformation related to its attempt to validate a manufacturingfacility in King of Prussia, Pa.The joint venture, called Immunization Products, gives ImmuneResponse control of clinical and regulatory affairs, and Rhone-Poulenc management of marketing and distribution. Thecompanies, which went into arbitration to settle disagreementsrelated to management of the project, have invested at least $55million in the effort. _ Jim Shrine

(c) 1997 American Health Consultants. All rights reserved.